Section 1: Introduction

Summary of recommendations and good practice points

Background
Target audience for the guideline
Groups covered within the guideline
Groups not covered
Scope of the guideline

Section 2: Methodology

Clinical questions and literature search
Appraisal of literature
Considered judgement and grading of evidence
Drafting the guideline
Declarations of interest
Guideline Development Group Members
Stakeholder organisations

Section 3: Epidemiology of NTM-pulmonary disease

Background
Epidemiology
Risk factors for NTM-pulmonary disease

Section 4: What is the evidence for transmission of NTM between individuals?

Evidence summary
Recommendation

Section 5: How should the lung disease attributable to NTM infection be defined?

Evidence summary
Recommendation
Good practice point

Section 6: What samples should be used to detect pulmonary NTM infection?

Evidence summary
Recommendations
Good practice points

Section 7: What microbiological tests should be used to detect NTM in respiratory samples?

Evidence summary
Recommendations
Good practice point

Section 8: What microbiological tests should be used to speciate and type NTM from respiratory samples?

Evidence summary
Recommendations

Section 9: Does in vitro DST predict response to antibiotic treatment in people with NTM-pulmonary infection?

Evidence summary
Recommendations
Good practice points

Section 10: What investigations should be performed in individuals suspected of having NTM-pulmonary disease?

Evidence summary
Respiratory tract cultures
Recommendations
Good practice points
Radiology
Recommendation
Computed tomography
Recommendation
Other investigations
Recommendations

Section 11: What factors influence when NTM treatment should be started?

Evidence summary
Microbiology
Clinical characteristics
Serology
Summary
Section 12: What antibiotic regimen should be used to treat NTM-PD?

Section 12a: What antibiotic regimen should be used to treat MAC-pulmonary disease?

Section 12b: What antibiotic regimen should be used to treat *M. kansasii*-pulmonary disease?

Section 12c: What antibiotic regimen should be used to treat *M. malmoense*-pulmonary disease?

Section 12d: What antibiotic regimen should be used to treat *M. xenopi*-pulmonary disease?

Section 12e: What antibiotic regimen should be used to treat *M. abscessus*-pulmonary disease?

Section 13: Is there a role for adjuvant therapies in the management of NTM-pulmonary disease?

Section 14: What investigations should be performed during treatment or following treatment for NTM-pulmonary disease?

Section 15: Are there differences in outcome between individuals with NTM-pulmonary disease treated in specialist versus non-specialist care settings?

Section 16: What is the role of surgery in the treatment of NTM-pulmonary disease?

Section 17: Does NTM infection affect an individual’s suitability for lung transplantation?

Section 18: NTM drug monograph
Contents

Rifampicin ii53
Streptomycin ii55
Tigecycline ii57

Section 19: Research recommendations
NTM epidemiology ii58
NTM microbiology ii58
NTM treatment ii58

References

Online appendices
The below documents are available at:
1. Clinical questions and literature search strategy
2. Evidence tables
3. Patient information